Proposal for Postmarketing Observational Registry Study:
Spark Therapeutics commits to conducting a multicenter, observational postmarketing safety registry. 
- Objective: To collect long-term safety information for patients treated with LUXTURNA for a period of five years after administration.
- Primary Focus: To monitor for adverse events of special interest, including but not limited to: development of oncologic or autoimmune diseases, eye inflammation and infection, sustained increased intraocular pressure, and retinal disorders.
- Population: The registry will aim to enroll at least 40 patients.
- Duration: 5-year follow-up period per patient.
- Assessments: Data will be collected from annual contacts with healthcare providers, including an annual ophthalmologic exam.